Clinical trials are necessary to establish its safety, efficacy, and appropriate human dosing
Description Active ingredient: 2mg/mL Hydroxocobalamin plus 4mg/mL Selenium For the treatment of cobalt deficiency and Vitamin B12 and Selenium responsive conditions in sheep and cattle
There is also a ClinicalTrials.gov listing for a phase 1 study described as assessing safety and pharmacokinetics of BPC-157 in healthy volunteers
Published clinical data supports accelerated initial response with the combination approach
Phase 2 cagrilintide weight-management trial Review of cagrilintide and related safety data ClinicalTrials.gov cagrilintide study listings Cagrilintide side effects are best understood as a pattern: digestive symptoms are common, while dehydration, allergic symptoms, severe abdominal pain, or glucose problems need timely review
Where BPC-157 tends to be more targeted toward connective tissue and the gut, TB-500 has broader systemic effects muscles, fascia, cardiac tissue, nerve healing
